HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
ID: 350461Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $3M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350461

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the HIV Vaccine Research and Design (HIVRAD) Program, aimed at supporting multi-disciplinary projects focused on the discovery of effective prophylactic vaccines against HIV/AIDS. This initiative encourages comprehensive research addressing critical scientific questions related to immune responses, vaccine vectors, and the evaluation of vaccine concepts in non-human primate models. The program anticipates funding 1-2 awards with a total budget of approximately $5 million for fiscal year 2025, with projects eligible for a maximum duration of five years. Interested applicants must comply with the NIH Data Management and Sharing Policy and submit their applications by March 13, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-037-Full-Announcement.html
    PAR-24-037.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is announcing the HIV Vaccine Research and Design (HIVRAD) Program intended to support comprehensive projects focused on developing effective prophylactic vaccines against HIV/AIDS. This Notice of Funding Opportunity (NOFO) encourages multi-disciplinary research addressing critical questions in vaccine discovery. It aims to investigate various aspects such as immune responses, vaccine vectors, and the use of non-human primate models. Eligible entities include higher education institutions, nonprofits, and various government entities. The program will fund 1-2 awards with a budget totaling approximately $5 million for fiscal year 2025, supporting projects for a maximum of five years. Applications must comply with the NIH Data Management and Sharing Policy, include a specific Plan for Enhancing Diverse Perspectives (PEDP), and are due by specified deadlines. The overall impact rating will consider significance, innovation, investigator qualifications, and project approach, ensuring a collaborative and scientific environment conducive to groundbreaking research. This initiative reflects NIH's ongoing commitment to addressing public health needs related to HIV prevention through robust scientific inquiry and innovation.
    Similar Opportunities
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD), aimed at advancing HIV-1 vaccine candidates from preclinical studies to clinical trial readiness. This program supports a range of activities including immunogenicity studies, manufacturing processes, and regulatory compliance, with a focus on innovative vaccine technologies that can elicit broadly neutralizing antibodies. The funding opportunity is significant in addressing ongoing health challenges related to the HIV/AIDS epidemic, with an award ceiling of $3 million and applications due by March 14, 2025. Interested applicants can find more information and submission details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Engineering Durable HIV Vaccine Responses (ENDURE)" to support research aimed at enhancing immune responses to HIV vaccines. This initiative, announced by the National Institute of Allergy and Infectious Diseases (NIAID), seeks to fund basic and applied research that elucidates factors contributing to durable immune responses, with a focus on innovative vaccine design and administration methods. The NIH plans to allocate up to $3 million for 2-4 grants in fiscal year 2025, with applications encouraged from a diverse range of organizations, including educational institutions and community-based organizations. Interested applicants should note that the application deadline is October 9, 2024, and are encouraged to submit a letter of intent to facilitate the review process; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Mechanisms of Inducing HIV Immunity in Early Life" (MIEL) under grant number RFA-AI-24-029. This initiative aims to support basic and applied research focused on understanding how immunity to HIV can be developed and maintained in children from birth to under 12 years old, particularly through the study of prophylactic vaccinations and broadly neutralizing antibodies (bNAbs). The NIH plans to commit $3 million for FY 2025 to fund 3-4 awards, with individual budgets not exceeding $750,000 per year. Applications are due by October 10, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01), a federal grant opportunity aimed at supporting early-stage investigators in the field of HIV/AIDS translational studies. This program is designed for individuals within ten years of completing their terminal professional degree or residency, providing three years of mentored research support focused on utilizing NHPs as preclinical models to advance understanding and treatment of HIV/AIDS. Successful applicants must hold a full-time appointment at an institution with NHP facilities and commit at least 75% of their professional effort to the program, with funding of up to $100,000 annually for salary and research expenses. Interested applicants should submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" aimed at supporting Early Stage Investigators (ESIs) in conducting innovative preclinical research on HIV/AIDS using NHP models. This grant initiative seeks to empower researchers who are within ten years of their terminal degree and have at least two years of postdoctoral experience, enabling them to explore new research directions that align with the NIH Strategic Plan for HIV and HIV-Related Research for FY 2021-2025. The funding provides a maximum of $400,000 over a two-year period, with applications due by September 7, 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.